Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四 環 醫 藥 控 股 集 團 有 限 公 司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
XUANYUENING, AN INNOVATIVE DRUG, FIRST INCLUDED IN THE NRDL

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, the "**Group**") is pleased to announce that the Bireociclib Tablets (brand name: Xuanyuening), an innovative drug independently developed by Xuanzhu Biopharmaceutical Co., Ltd. ("**Xuanzhu Biopharm**"), a non wholly-owned subsidiary of Sihuan Pharmaceutical, has been included for the first time in the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2025) (the "**2025 NRDL**"). The 2025 NRDL will officially take effect on January 1, 2026.

Xuanzhu Biopharm is able to further enhance the affordability and accessibility of Xuanyuening among patients after the discussion on the medical insurance, which will facilitate the promotion of its market presence and increase sales volume, resulting in a significant impact on the long-term business development of Xuanzhu Biopharm. Xuanzhu Biopharm will make a cooperative effort to implement medical insurance policies, continue to promote the admission of hospitals, expand the core market and broaden market coverage, with a view to continuously improving drug accessibility for patients.

ABOUT BIREOCICLIB

Bireociclib Tablets (brand name: Xuanyuening), as a novel CDK2/4/6 inhibitor, possesses a unique multi-target synergistic mechanism of action, offering advantages such as potent inhibition of tumor cell proliferation and a significant reduction in hematological toxicity commonly associated with traditional CDK4/6 inhibitors. Bireociclib was approved by the National Medical Products Administration on May 2025, for use in combination with Fulvestrant for the treatment of patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) ("**HR+/HER2-**") advanced or metastatic breast cancer whose disease has progressed after prior endocrine therapy, and as a monotherapy for HR+/HER2- advanced or metastatic breast cancer patients who have progressed after receiving two or more lines of endocrine therapies and one chemotherapy in the metastatic stage, making it the first and only CDK4/6 inhibitor in the PRC approved for a monotherapy indication. Two approved indications have been included in the 2025 NRDL. In addition to the two approved indications mentioned above, the supplementary new drug application ("**sNDA**") for Bireociclib in combination with aromatase inhibitor (AI) for the first-line treatment of HR+/HER2-advanced breast cancer is under review.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights. The company has a first-class research and development ("**R&D**") team, all core personnel have years of experience in new drug research and development. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, December 8, 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.